Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial-Reference-Cited by-同舟云学术

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

Published:2016-02-11 Issue:5 Volume:114 Page:505-509
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Tebbutt Niall C, ,Price Timothy J,Ferraro Danielle A,Wong Nicole,Veillard Anne-Sophie,Hall Merryn,Sjoquist Katrin M,Pavlakis Nick,Strickland Andrew,Varma Suresh C,Cooray Prasad,Young Rosemary,Underhill Craig,Shannon Jennifer A,Ganju Vinod,Gebski Val

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015440.pdf

Reference18 articles.

1. Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E Arbeitsgemeinschaft Internistische Onkologie (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internisticsche Onkologie. J Clin Oncol 26 (9): 1435–1442.

2. Cook N, Marshall A, Blazeby J, Bridgewater J, Wadsley J, Coxon F, Mansoor W, Madhusudan S, Falk S, Middleton G, Swinson D, Chau I, Thompson J, Cunningham D, Kareclas P, Dunn J, Ford H (2013) Cougar-01: a randomised phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol 31 (15–suppl): abstract 4023.

3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36–46.

4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163–168.

5. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (20): 2040–2048.

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in construction and release of natural polysaccharide-platinum nanomedicines: A review;International Journal of Biological Macromolecules;2023-10

2. Advances in the Theranostics of Oesophageal Squamous Carcinoma;Advanced Therapeutics;2023-04-16

3. Peptide mediated therapy in fibrosis: Mechanisms, advances and prospects;Biomedicine & Pharmacotherapy;2023-01

4. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis;Scientific Reports;2022-12-20

5. Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma;Cancers;2022-12-07